ZooMAb® antibodies represent an entirely new generation of recombinant monoclonal antibodies.Each ZooMAb® antibody is manufactured using our proprietary recombinant expression system, purified to homogeneity, and precisely dispensed to produce robust and highly reproducible lot-to-lot consistency. Only top-performing clones are released for use by researchers. Each antibody is validated for high specificity and affinity across multiple applications, including its most commonly used application. ZooMAb® antibodies are reliably available and ready to ship when you need them.
Clone 1C22 is a ZooMAb® Rabbit recombinant monoclonal antibody that specifically detects mTOR phosphorylated on serine 2448.
KLH-conjugated linear peptide corresponding to 11 amino acids surrounding phosphoserine 2448 from the C-terminal region of human Serine/threonine-protein kinase mTOR.
Quality Control Testing
Evaluated by Western Blotting in lysate from NIH3T3 cells treated with insulin.
Western Blotting Analysis (WB): A 1:1,000 dilution of this antibody detected mTOR phosphorylated on serine 2448 in NIH3T3 cells, overnight serum stared and treated with insulin (500 nM for 15 min.).
Western Blotting Analysis: A 1:1,000 dilution from a representative lot detected phospho-mTOR-(Ser2448) in lysate from HEK293 cells overnight serum starved and treated with EGF (50 ng/mL; 10 min).
Immunohistochemistry (Paraffin) Analysis: A 1:100 dilution from a representative lot detected phospho-mTOR-(Ser2448) in human prostate cancer and human stomach cancer tissue sections.
Peptide Inhibition Assay: Target band detection in a lysate from NIH3T3 cells treated EGF (50 ng/mL; 10 min) was prevented by preblocking of a representative lot with the immunogen phosphopeptide, but not the corresponding non-phosphopeptide.
Immunocytochemistry Analysis: A 1:100 dilution from a representative lot detected phospho-mTOR-(Ser2448) in HEK293 cells overnight serum starved and treated with EGF (50 ng/mL; 10 min)..
Note: Actual optimal working dilutions must be determined by end user as specimens, and experimental conditions may vary with the end user
Serine/threonine-protein kinase mTOR (UniProt: P42345; also known as EC:188.8.131.52, FK506-binding protein 12-rapamycin complex-associated protein 1, FKBP12-rapamycin complex-associated protein, Mammalian target of rapamycin, mTOR, Mechanistic target of rapamycin, Rapamycin and FKBP12 target 1, Rapamycin target protein 1) is encoded by the MTOR (also known as FRAP, FRAP1, FRAP2, RAFT1, RAPT1) gene (Gene ID: 2475) in human. mTOR is an evolutionarily conserved serine/threonine kinase that acts as a nutrient sensor and regulates growth factor signaling and cellular metabolism. Its catalytic kinase domain, located in the C-terminal region, exhibits a strong homology to the catalytic domain of PI 3-kinase and PI 4-kinase. It activates translation initiation in response to both hormonal and nutrient signals by phosphorylating at least two translational modulators, p70S6 kinase 1 (S6K1) and eIF-4E-binding protein 1. Cellular mTOR is composed of two large protein complexes, known as mTORC1 and mTORC2. The mTORC1 complex is sensitive to rapamycin and consists of mTOR, Raptor, and mLST8 and two negative regulators, PRAS40 and DEPTOR. The Raptor unit serves as a scaffolding protein to bridge the interaction between mTOR and its substrates. The mTORC2 complex that is insensitive to rapamycin, contains mTOR, Rictor, Sin1, and mLST8 and the newly identified components Protor, Hsp70 and DEPTOR. This complex plays a role in actin cytoskeleton organization and phosphorylates Akt on Ser473 to fully activate it. mTOR undergoes phosphorylation on serine 2448 by the action of p70S6 kinase as well as Akt. P70S6 kinase is a major effector of mTOR phosphorylation at this site in response to both mitogen- and nutrient-derived stimuli. Rapamycin is shown to block serum-stimulated phosphorylation of ser 2448. Deregulation of multiple elements of the mTOR pathway has been reported in many types of cancers. This ZooMAb® recombinant monoclonal antibody, generated by our propriety technology, offers significantly enhanced specificity, affinity, reproducibility, and stability over conventional monoclonals. (Ref.: Hoeffer, CA., and Klann, E. (2010). Trends Neurosci. 33(2); 67-75; Chiang, GG., and Abraham, RT. (2005). J. Biol. Chem. 280(27); 25485-25490).
Purified recombinant rabbit monoclonal antibody IgG, lyophilized in PBS, 5% Trehalose, normal appearance a coarse or translucent resin. The PBS/trehalose components in the ZooMAb formulation can have the appearance of a semi-solid (bead like gel) after lyophilization. This is a normal phenomenon. Please follow the recommended reconstitution procedure in the data sheet to dissolve the semi-solid, bead-like, gel-appearing material. The resulting antibody solution is completely stable and functional as proven by full functional testing. Contains no biocide or preservatives, such as azide, or any animal by-products. Larger pack sizes provided as multiples of 25 μL.
300 μg/mL after reconstitution at 25 μL per vial. Please refer to guidance on suggested starting dilutions and/or titers per application and sample type.
Storage and Stability
Recommend storage of lyophilized product at 2-8°C; Before reconstitution, micro-centrifuge vials briefly to spin down material to bottom of the vial; Reconstitute each vial by adding 25 μL of filtered lab grade water or PBS; Reconstituted antibodies can be stored at 2-8°C, or -20°C for long term storage. Avoid repeated freeze-thaws.
ZooMAb is a registered trademark of Merck KGaA, Darmstadt, Germany
Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.